logo
Share SHARE
FONT-SIZE Plus   Neg

Apple Releases Developer Preview Of OS X Mavericks - Quick Facts

Apple Inc. (AAPL) on Monday released a developer preview of OS X Mavericks, the 10th major release of its advanced operating system.

With more than 200 new features, OS X Mavericks brings Maps and iBooks to the Mac, introduces Finder Tags and Tabs, enhances multi-display support for power users, delivers new core technologies for breakthrough power efficiency, and includes an all new version of Safari.

The preview release of OS X Mavericks is available to Mac Developer Program members starting today. Mac users will be able to download Mavericks from the Mac App Store this fall.

"OS X Mavericks is our best version yet and features new Maps and iBooks apps, Finder Tags and Tabs, enhanced multi-display support, performance and energy saving features, and an all new Safari," said Craig Federighi, Apple's senior vice president of Software Engineering.

Additional features in OS X Mavericks include: iCloud Keychain, which safely stores website login information, credit card numbers and Wi-Fi passwords; an updated Calendar, which adds integration with Maps; and interactive Notifications, allowing users to reply to a message, respond to a FaceTime call or even delete an email without leaving the app one is using.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The European Union's executive arm has ordered the Irish government to recover up to 13 billion euros, or $14.5 billion, in taxes from Apple Inc. The European Commission said it has concluded that Ireland granted the U.S. tech giant undue tax benefits of up to 13 billion euros, which is illegal under EU state aid rules. Shares of Apple are down 1 percent in pre-market activity. Abercrombie & Fitch Co. (ANF) reported Tuesday a wider year-over-year net loss for the second-quarter, hurt by a impairment charge. Net sales for the quarter were down 4%, with comparable sales declined 4%. Quarterly loss was wider than their expectations, but revenues beat their' estimates. The performance of Biotech stocks thus far this month is nothing to write home about, if we were to look at it from the standpoint of the movement of the NYSE Arca Biotechnology Index. A peek at what transpired on the FDA front in August and a preview of what September holds in store for us look pertinent.
comments powered by Disqus
Follow RTT